IJCRRI Journ Cur Res ReInternational Journal of Current Research and ReviewI Journ Cur Res Re2231-21960975-5241Radiance Research Academy2208HealthcarePHARMACEUTICAL RESEARCH AND DEVELOPMENT -CASE STUDY OF INDIAN PHARMACEUTICAL INDUSTRY JanodiaManthan D.D.SreedharS.LigadeVirendraPiseAjay GUdupaNayanabhirama)3240This article is copyright of Popeye Publishing, 20092009This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

Pharmaceutical Research and Development (RandD) is time consuming, risky and costly. It takes roughly about USD 1 billion to develop and commercialize a new drug. Indian pharmaceutical companies were not engaged in basic research and the amount spent on RandD was very low. With adherence to Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement Indian pharmaceutical companies have increase the amount spent on RandD. This study discusses the current RandD scenario in India.